340 related articles for article (PubMed ID: 22728908)
21. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
Tomiyama H; Motobe K; Zaydun G; Koji Y; Yambe M; Arai T; Kushiro T; Yamashina A
Am J Hypertens; 2005 Feb; 18(2 Pt 1):178-82. PubMed ID: 15752944
[TBL] [Abstract][Full Text] [Related]
22. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
Malik RA; Schofield IJ; Izzard A; Austin C; Bermann G; Heagerty AM
Hypertension; 2005 Feb; 45(2):264-9. PubMed ID: 15630048
[TBL] [Abstract][Full Text] [Related]
23. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
24. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
25. Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.
Kishi T; Hirooka Y; Sunagawa K
Hypertens Res; 2012 Sep; 35(9):940-6. PubMed ID: 22573203
[TBL] [Abstract][Full Text] [Related]
26. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
28. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
30. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
31. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling.
Takai S; Kirimura K; Jin D; Muramatsu M; Yoshikawa K; Mino Y; Miyazaki M
Hypertens Res; 2005 Jul; 28(7):593-600. PubMed ID: 16335888
[TBL] [Abstract][Full Text] [Related]
32. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
[TBL] [Abstract][Full Text] [Related]
33. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
34. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Takagi H; Mizuno Y; Yamamoto H; Goto SN; Umemoto T;
Hypertens Res; 2013 Apr; 36(4):368-73. PubMed ID: 23235712
[TBL] [Abstract][Full Text] [Related]
35. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.
Perrone-Filardi P; Corrado L; Brevetti G; Silvestro A; Dellegrottaglie S; Cafiero M; Caiazzo G; Petretta A; Maglione A; Monda C; Guerra G; Marzano A; Cesarano P; Gargiulo P; Chiariello M
J Clin Hypertens (Greenwich); 2009 May; 11(5):260-5. PubMed ID: 19534023
[TBL] [Abstract][Full Text] [Related]
36. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
37. Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Okano Y; Tamura K; Masuda S; Ozawa M; Tochikubo O; Umemura S
Clin Exp Hypertens; 2009 Nov; 31(8):680-9. PubMed ID: 20001460
[TBL] [Abstract][Full Text] [Related]
38. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
[TBL] [Abstract][Full Text] [Related]
39. Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome.
Brillante DG; O'Sullivan AJ; Brillante RE; Howes LG
Blood Press; 2009; 18(3):142-8. PubMed ID: 19462315
[TBL] [Abstract][Full Text] [Related]
40. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
